ECM Development Prospects: Market Size, Hallmarks of Aging, and Investment Trends

I. Why ECM Is the "Next-Generation Anti-Aging Material"

In 2025, the extracellular matrix (ECM) was officially listed as the thirteenth hallmark of aging (based on an extension of the <i>Cell</i> hallmarks of aging framework, widely cited by academia and industry). Since the hallmarks of aging framework was first proposed, it has continued to expand, and in recent years it has elevated "ECM imbalance" from the single-cell level to the tissue microenvironment level—meaning the mainstream consensus in aging research has shifted from "looking at individual cells" to "looking at the microenvironment in which cells live": ECM degradation, crosslinking, and stiffening are recognized as important mechanisms driving skin aging and tissue degeneration.

This cognitive shift directly rewrites the evaluation criteria for anti-aging materials: in the past, the question was "what ingredient was added"; now it is "whether the environment in which cells live has been rebuilt." ECM happens to be "the environment itself"—it is not a single active substance, but an aggregate of support, signaling, and reserve, and is therefore regarded by industry as the "next-generation anti-aging material."

At the same time, ECM product forms are also evolving rapidly: from early decellularized ECM (dECM) patches for tissue repair, to hydrogels and micronized ECM, and then to injectable ECM formulations. The "micronization + injectability" of forms is a key step in its move from medical devices to medical aesthetics and skincare, and is also the basis on which new concepts such as ECM injection and regenerative aesthetics can be established. When ECM can be injected like hyaluronic acid (HA) and applied like a serum, its market imagination expands from "medical consumables" to "consumer products."

II. Global and China Market Size (Multiple Calibers)

Looking at the global ECM market, the base of $2.15 billion is not large, but two clues deserve attention: first, dECM already accounts for 51.1% of the ECM market, indicating that the "decellularization" technology route is the absolute main force in current ECM industrialization; second, China's ECM products were about RMB 10.7 billion in 2025 and are expected to reach RMB 12 billion in 2026, with the Chinese market size far exceeding the global public caliber—this is directly related to rising medical aesthetics penetration in China and the approval and ramp-up of regenerative products, and also means that growth in the dECM market is mainly driven by device-based and medical aesthetics demand in China. The two figures in the comparison group illustrate the stage of the track: HA's global $12.85 billion is "today's money," recombinant collagen's 28.5% CAGR is "next year's money," and ECM's $2.15 billion is "the day after tomorrow's money."

III. Drivers: Four Forces Moving in the Same Direction

1. High growth in regenerative medicine and tissue engineering. The global tissue engineering market grew from $11.26 billion in 2021 to $31.23 billion in 2030 (CAGR 10.46%, PMC review), and ECM biomaterials are one of its most core ingredient categories. The demand for scaffold materials in tissue engineering naturally points to ECM—it is both a structural scaffold and a signal carrier, with almost no substitute.

2. Rising medical aesthetics penetration and the emergence of "regenerative aesthetics." Medical aesthetics is moving from "filling" to "regeneration": regenerative aesthetics has become the main narrative axis for high-end institutions and upstream manufacturers, and ECM products naturally fit this trend because of their mechanism of "inducing self-repair." Compared with "injecting something to prop it up," "letting tissue grow back on its own" is a narrative that better supports high premiums.

3. Accelerating aging. Global aging is driving up demand for skin repair, wound healing, and bone and joint regeneration, and the core target in these scenarios is ECM. Anti-aging is extending from "vanity projects" to more indications such as joints, oral cavity, and intimate care, and ECM's application scope is expanding accordingly.

4. Domestic substitution of raw materials. The maturation of domestic ingredient technologies such as recombinant collagen and fermented HA and falling costs are moving ECM-type ingredients from "high-priced imports" to "scalable availability," opening space for downstream brands and OEM. Domesticization of the supply chain not only reduces costs, but also greatly shortens the development cycle for products that use ECM as a selling point.

The four forces are not isolated but mutually amplifying: the regenerative narrative of medical aesthetics creates demand scenarios for ECM, advances in regenerative medicine provide the technological foundation, aging ensures the long-term nature of demand, and domesticization fills the cost and supply gaps. Particularly noteworthy is the uniqueness of the Chinese market—in the global caliber, ECM is still mainly tissue repair medical devices, while incremental growth in China comes more from medical aesthetics and functional skincare, meaning Chinese brands have an opportunity to define the "consumer product form of ECM" first, before the global ECM narrative has taken shape.

IV. Industry Developments: Giants Are Densely Positioning (2026)

• Bloomage Biotech: Humanized biomimetic ECM Class III medical devices have entered the pilot scale-up stage, with a leading company formally betting on the ECM device route (36Kr);
• Imeik: In July 2026, it invested in Huaxia Biology, holding 15.64%, and obtained exclusive distribution rights for its ECM products in Greater China—a dual binding of channel and ingredient (36Kr);
• Huadong Medicine: Its Xinkeli Aesthetics reached an exclusive strategic cooperation in China with Meibai Biology for ECM collagen MB007, bringing ECM collagen into the medical aesthetics segment (36Kr);
• Scientific research direction: dECM combined with 3D bioprinting and bioinks is becoming a frontier intersection of tissue engineering and regenerative medicine (PMC review).

From the perspective of capital flows in ECM investment, the characteristic of 2026 is "leading listed companies + exclusive rights + device-based": all three representative collaborations point to the same judgment—ECM is the next high ground in medical aesthetics ingredients after collagen and HA. Particularly noteworthy are "ECM collagens" such as MB007: what giants are competing for is no longer just recombinant collagen itself, but ingredients obtained from ECM extracts that contain a complete signaling environment, suggesting that next-generation products will no longer be "upgraded versions" of a single ingredient, but "reconstructed versions" at the microenvironment level.

V. Challenges: Standardization, Regulation, and Capacity

The prospects are clear, but ECM industrialization still faces three major thresholds.

Standardization and batch consistency. ECM comes from natural tissues or complex biosynthesis, with diverse components and naturally occurring batch differences. How to establish quantifiable quality control standards (composition profile, activity, immunogenicity) is an industry-level challenge. By contrast, HA and recombinant collagen can both be precisely characterized by molecular weight and purity, and ECM's "hard-to-explain" nature is both a barrier and a regulatory obstacle.

Regulatory oversight. ECM products span the regulatory boundaries of cosmetics, Class II/Class III medical devices, and drugs, with large differences in registration pathways across regions, long compliance cycles, and high costs. At present, what can move first in cosmetics scenarios is mostly conceptual addition, while what truly scales is still devices and injectables—and this path places extremely high demands on companies' registration capabilities.

Scaled capacity. Both decellularization processes and biosynthesis scale-up face capacity bottlenecks, and unstable ingredient supply will directly constrain downstream product ramp-up. Capacity ramp-up for ECM ingredients is slower than for fermentation-based ingredients, which determines that first movers can enjoy a longer supply dividend.

These three thresholds also mean: whoever first gets through "standardization + compliance + mass production" can occupy the first-mover dividend in the ECM track. But precisely because the thresholds are high, ECM will not repeat HA's "red-ocean involution"—players with self-developed ingredients, registration filing, and large-scale production capabilities will have long-term barriers, and these are exactly the three dimensions most worth examining when B-end customers choose partners.

VI. Opportunity Window and Layout Suggestions for B-End Players

For brands, OEM, and medical aesthetics institutions, the ECM opportunity window is concentrated in the next 3-5 years.

• Brands: Use ECM/dECM concepts to build high-end product lines and form a "base portfolio + upgrade portfolio" combination with HA and collagen; lock in compliant ingredients and patents as early as possible to avoid the concept heating up first while ingredients get bottlenecked;
• OEM/contract manufacturers: Lay out process reserves for ECM-type formulations in advance (dispersion, stability, activity retention), solve the stability challenges of ECM ingredients in formulations, and become brands' partner for landing "from 0 to 1"—this is a key window for OEM to build differentiated competitiveness;
• Medical aesthetics institutions: Track the approval pace of injectable ECM and regenerative filler products, and establish a "regenerative aesthetics" project portfolio as soon as products are compliant, seizing the mindshare of high-end customers.

For upstream ingredient suppliers, the order of investment now should be: first solve batch consistency (the premise of all downstream trust), then discuss concepts and channels. Weitai Group's velubio.com focuses on collagen and ECM biological ingredient supply, and zhenmeifu.com provides cosmetics OEM services, which can help brands position early in ingredient selection, formulation development, and production landing.

VII. Outlook for 2032

By 2032, ECM is expected to stand alongside collagen and HA as the "three pillars" of anti-aging ingredients, when the global ECM market will reach $3.81 billion—and what is truly scarce is not the ingredient itself, but companies that can clearly explain "microenvironment reconstruction," achieve compliance, and mass produce.

Further reading: To learn more about collagen and ECM ingredients, please visit Velubio; for one-stop cosmetics and medical aesthetics OEM services, please visit Zhenmeifu.